The Herald

Radiothera­py doesn’t improve breast cancer survival figures over 30 years

-

ONE of the longest-ever follow up studies of breast cancer patients has found that radiothera­py does not appear to improve survival after 30 years.

Researcher­s found that radiothera­py with either chemothera­py or the hormone drug tamoxifen after surgery does reduce the risk of the disease returning in the subsequent 10 years.

But it makes little difference to that risk thereafter, researcher­s said.

Nor does it improve overall survival after 30 years, according to the new study, which is being presented to the European Breast Cancer Conference in Spain.

But other academics point out that the women included in the study initially had treatment three decades ago, and since then more sophistica­ted radiothera­py treatment techniques have been developed.

The research, led by Ian Kunkler, honorary professor of clinical oncology at the University of Edinburgh, forms one of the longest follow-up studies tracking patients who received breast conserving surgery.

The Scottish breast conservati­on trial tracked 585 patients for 30 years.

All of the patients were under the age of 70 at the start of the study and they were all diagnosed with early breast cancer.

After surgery they were given chemothera­py or tamoxifen, depending on whether or not their cancer was driven by the hormone oestrogen.

Half of the patients also had radiothera­py.

A decade after initial treatment, the risk of breast cancer recurring in the same breast was reduced by more than 60% among the group who had received radiothera­py compared to those who did not.

But, after the 10-year mark, the risk of recurrence was similar in both groups.

Meanwhile, 30 years after their treatment, 24% of women who had radiothera­py were still alive compared to 27.5% of those who did not.

“Long-term follow-up is essential in breast cancer trials so that we can understand the full picture,” Prof Kunkler said.

“These data challenge the idea that radiothera­py improves longterm survival by preventing recurrence­s of cancer in the same breast.”

He added: “We found that there is no long-term improvemen­t in overall survival for those women having radiothera­py.

“This may be because, although radiothera­py may help to prevent some breast cancer deaths, it may also cause a few more deaths, particular­ly a long time after the radiothera­py, from other causes such as heart and blood vessel diseases.

“The benefits of having radiothera­py in terms of fewer local recurrence­s are only accrued over the first 10 years after radiothera­py; thereafter, the rate of local recurrence is similar whether or not patients had radiothera­py.

“Patients with breast cancer can live for decades after treatment for the disease.”

Prof Kunkler added: “It’s important to note that every woman with breast cancer is different and will have different forms of the disease.”

 ?? ?? Study was led by an Edinburgh university professor
Study was led by an Edinburgh university professor

Newspapers in English

Newspapers from United Kingdom